Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

NCT06398275 is registered in ClinicalTrials.gov with University Hospital of Split as lead sponsor.

NCT NCT06398275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06398275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty
Lead sponsor
University Hospital of Split
Phase
Phase 2
Overall status
Unknown status
Start date
March 6, 2024
Completion date
December 31, 2024
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

emergence delirium, remimazolam, rhinoplasty